Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Influence Over Rx Industry Could Change Culture At FDA – Millennium

Executive Summary

The increasing influence of the Centers for Medicare & Medicaid Services within the prescription drug industry could create opportunities for a "cultural shift" at FDA, Millennium Senior VP-R&D Strategy and Operations Abie Celniker said

You may also be interested in...

Detour On FDA’s “Critical Path:” Safety Issues Divert Agency’s Attention

FDA has revised its timeline for the "Critical Path" drug development initiative to reflect more pressing matters, including drug safety issues, Acting Deputy Commissioner for Operations Janet Woodcock said

Biomarker Working Group To Explore Development Of Guidance

An FDA working group will be formed by year-end to consider the development of a guidance on biomarkers

Medicare Rx Means “Dramatic” Change For Pharma; CMS Is New FDA – Scully

The Medicare drug benefit will make the Centers for Medicare & Medicaid Services at least as important to the pharmaceutical market as FDA, former CMS Administrator Tom Scully predicts





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts